<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/2072-0351-5868</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-5868</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Общее руководство Международной Диабетической Федерации по сахарному диабету 2 типа (краткое изложение)</article-title><trans-title-group xml:lang="en"><trans-title>Obshchee rukovodstvo Mezhdunarodnoy Diabeticheskoy Federatsii po sakharnomu diabetu 2 tipa (kratkoe izlozhenie)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гурьева</surname><given-names>Ирина Владимировна</given-names></name><name name-style="western" xml:lang="en"><surname>Gur'eva</surname><given-names>Irina Vladimirovna</given-names></name></name-alternatives><email xlink:type="simple">-</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Федеральное бюро медико-социальной экспертизы, Москва; Российская медицинская академия последипломного образования, Москва</institution></aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>15</day><month>12</month><year>2007</year></pub-date><volume>10</volume><issue>4</issue><issue-title>№4 (2007)</issue-title><fpage>54</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гурьева И.В., 2007</copyright-statement><copyright-year>2007</copyright-year><copyright-holder xml:lang="ru">Гурьева И.В.</copyright-holder><copyright-holder xml:lang="en">Gur'eva I.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/5868">https://www.dia-endojournals.ru/jour/article/view/5868</self-uri><abstract><p>Настоящее Руководство представляется значительным достижением в обобщении международного опыта, в области сахарного диабета 2 типа и, несомненно, долж- но быть известно широкому кругу врачей ? не только эндокринологам, но и терапевтам и всем специалистам, работающим с осложнениями сахарного диабета.</p></abstract><kwd-group xml:lang="ru"><kwd>Международная диабетическая федерация</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>руководство</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Business Briefing. European Endocrine review 2006. A report by W.J.M. Wientiens. P.14.</mixed-citation><mixed-citation xml:lang="en">Business Briefing. European Endocrine review 2006. A report by W.J.M. Wientiens. P.14.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Business Briefing. European Endocrine review 2006. Prevention through Awareness - Raising Global Awareness of Diabetes and its Complications. P.Lefebre and Anne Pierson. P.24-26. www.touchbriefings.com</mixed-citation><mixed-citation xml:lang="en">Business Briefing. European Endocrine review 2006. Prevention through Awareness - Raising Global Awareness of Diabetes and its Complications. P.Lefebre and Anne Pierson. P.24-26. www.touchbriefings.com</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Global Guidelines for Type 2 Diabetes. International Diabetes Federation,2005:1-79.</mixed-citation><mixed-citation xml:lang="en">Global Guidelines for Type 2 Diabetes. International Diabetes Federation,2005:1-79.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Definition. Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of WHO Consultation. Part 1:Diagnosos and Classification of Diabetes Mellitus. Geneva:WHO Department of noncommunicable Disease Surveillance, 1999:1-59. http:/www.who.int</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Definition. Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of WHO Consultation. Part 1:Diagnosos and Classification of Diabetes Mellitus. Geneva:WHO Department of noncommunicable Disease Surveillance, 1999:1-59. http:/www.who.int</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association: Position Statement. Tests of glycemia in diabetes.Diabetes Care,2004.27(Suppl.1.) S.91-93.</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association: Position Statement. Tests of glycemia in diabetes.Diabetes Care,2004.27(Suppl.1.) S.91-93.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mclntosh A., Hattchinson A., Home PD, et al. Clinical guidlinesand evidence review for type 2 diabetes:management of blood glucose. 2001.http://www.nice.org.uk/pdf/NICE_full_blood_glucose.pdf</mixed-citation><mixed-citation xml:lang="en">Mclntosh A., Hattchinson A., Home PD, et al. Clinical guidlinesand evidence review for type 2 diabetes:management of blood glucose. 2001.http://www.nice.org.uk/pdf/NICE_full_blood_glucose.pdf</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diab.Med1999;16:716- 30.http://www.staff.ncl.ac.uk/Philip.home/guidelines</mixed-citation><mixed-citation xml:lang="en">European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diab.Med1999;16:716- 30.http://www.staff.ncl.ac.uk/Philip.home/guidelines</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Gray A.,Raikou M., Fenn P., et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomized controlled trial (UKPDS)41.BMG 2000;320:1373-78.</mixed-citation><mixed-citation xml:lang="en">Gray A.,Raikou M., Fenn P., et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomized controlled trial (UKPDS)41.BMG 2000;320:1373-78.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Canadian Diabetes Association Clinical Practice Guideline Expert committee. Canadian Diabetes association Clinical Practice Guidelines for prevention and Management of Diabetes in Canada. Canadian Journal of Diabetes 2003;27(Suppl2):S37-42.htt://www.diabetes.ca</mixed-citation><mixed-citation xml:lang="en">Canadian Diabetes Association Clinical Practice Guideline Expert committee. Canadian Diabetes association Clinical Practice Guidelines for prevention and Management of Diabetes in Canada. Canadian Journal of Diabetes 2003;27(Suppl2):S37-42.htt://www.diabetes.ca</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Institute for Clinical Systems Improvement (Bloomington, MIN, USA). Management of Type 2 Diabetes Mellitus,2004.http://www.icsi.org/knowlege</mixed-citation><mixed-citation xml:lang="en">Institute for Clinical Systems Improvement (Bloomington, MIN, USA). Management of Type 2 Diabetes Mellitus,2004.http://www.icsi.org/knowlege</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nesto R.W.,Bell D., Bonow R.O. et al.Tiozolidindione use, fluid retention, and congestive heart failure. A concensus statement from the American heart Associationand American Diabetes association. Diabetes Care 2004;27:256-63.</mixed-citation><mixed-citation xml:lang="en">Nesto R.W.,Bell D., Bonow R.O. et al.Tiozolidindione use, fluid retention, and congestive heart failure. A concensus statement from the American heart Associationand American Diabetes association. Diabetes Care 2004;27:256-63.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
